I agree.....and much or all of the doubt and risk could be eliminated one morning when we wake to a PR announcing a license deal. NP and the BOD know we need it and seems they are no longer considering going alone (Syneos Health commercialization plan sitting on the shelf as a backup plan) as they know this will require a lot of funding that we do not have and was likely a negotiating tactic when previously discussed.

A PR with $90M milestones will likely allow them to get a short-term loan if needed if the deal does not have enough included in up-front payments. Once the financing concerns are resolved the dominoes will begin falling.....share price appreciation, up-listing, analysts coverage, institutional ownership, BLA approval, revenues......and this awesome and long-awaited cycle would continue for a prolonged period with all the other indications IMO.......all triggered by a license deal and the financing needed to get combo HIV to approval.

I concur the last offering was a failure. While a license deal wouldn't absolve them of this blunder, it would largely be forgotten and unimportant with a much needed and expected jump in the share price upon such announcement.